Skip to content
- Peterson E, et al. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observation from a phase III trial. Support Care Cancer 2013;21:2341-9.
- Busaidy N, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR patchway. J Clin Oncol 2012;30(23).
- Aapro M, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol 2014;4:763-73.
- Alasker A, et al. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer Treat Rev 2013;39(4):388-401.
- Funakoshi T, et al. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol 2013;52(4):691-702.
- Clemons J, et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer 2012;10(4):225-31.